Higher glucose levels associated with worse pathologic response and survival in patients with locally advanced gastric cancer treated with neoadjuvant immunotherapy

Abstract Background The impact of type 2 diabetes mellitus (T2DM) and glucose levels on clinical outcomes in patients with gastric cancer after neoadjuvant immunotherapy remains unclear. We assessed mean baseline glucose and T2DM status in relation to pathologic response and survival. Methods This retrospective cohort study included patients with gastric cancer who received NICT followed by surgery at three medical centers in China from 2021 to 2024. Random venous glucose levels within 4 weeks before ICI initiation, and T2D status, OS and PFI were collected. Results Among 376 patients, 86 (22.9%) had diabetes and 91 (24.2%) achieved pCR. Compared with the lowest glucose quartile, the highest quartile had a lower pCR rate (14.9% vs 28.0%) and lower adjusted odds of pCR (OR 0.33, 95% CI 0.15 to 0.74, P = 0.007). The adjusted HR for OS comparing the highest with the lowest quartile was 3.42 (95% CI 0.97 to 12.01, P = 0.055). PFI did not differ significantly across quartiles (log-rank P = 0.189). Diabetes was not associated with pCR or survival. Among 175 patients with available CPS data, CPS ≥ 5 was associated with higher odds of pCR and longer OS and PFI after adjustment. HbA1c was not significantly associated with treatment outcomes in the 59 patients with available data. Conclusion Higher mean baseline glucose was associated with poorer pathologic response and shorter survival for gastric cancer patients underwent NIT. These findings highlight the value of baseline glucose assessment and glycemic control may improve treatment outcomes.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11356734/v1
Primary Topic
Gastric Cancer Management and Outcomes
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Higher glucose levels associated with worse pathologic response and survival in patients with locally advanced gastric cancer treated with neoadjuvant immunotherapy

Yuxin Zhong, Bixian Luo, Weihua Gong, Chengyu Hu et al.
2 links
Research Square
Gastric Cancer Management and Outcomes
preprint

Higher glucose levels associated with worse pathologic response and survival in patients with locally advanced gastric cancer treated with neoadjuvant immunotherapy

Yuxin Zhong, Bixian Luo, Weihua Gong, Chengyu Hu, Dong Cao, Hongming Liu, Fuping Li, Yong Liu, Jun He, Chuanlei Tuo
preprint en

Abstract

Abstract Background The impact of type 2 diabetes mellitus (T2DM) and glucose levels on clinical outcomes in patients with gastric cancer after neoadjuvant immunotherapy remains unclear. We assessed mean baseline glucose and T2DM status in relation to pathologic response and survival. Methods This retrospective cohort study included patients with gastric cancer who received NICT followed by surgery at three medical centers in China from 2021 to 2024. Random venous glucose levels within 4 weeks before ICI initiation, and T2D status, OS and PFI were collected. Results Among 376 patients, 86 (22.9%) had diabetes and 91 (24.2%) achieved pCR. Compared with the lowest glucose quartile, the highest quartile had a lower pCR rate (14.9% vs 28.0%) and lower adjusted odds of pCR (OR 0.33, 95% CI 0.15 to 0.74, P = 0.007). The adjusted HR for OS comparing the highest with the lowest quartile was 3.42 (95% CI 0.97 to 12.01, P = 0.055). PFI did not differ significantly across quartiles (log-rank P = 0.189). Diabetes was not associated with pCR or survival. Among 175 patients with available CPS data, CPS ≥ 5 was associated with higher odds of pCR and longer OS and PFI after adjustment. HbA1c was not significantly associated with treatment outcomes in the 59 patients with available data. Conclusion Higher mean baseline glucose was associated with poorer pathologic response and shorter survival for gastric cancer patients underwent NIT. These findings highlight the value of baseline glucose assessment and glycemic control may improve treatment outcomes.

Research Square
Shaoxing University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Second Affiliated Hospital of Zhejiang University (CN), Tianjin Medical University (CN), Fuzhou University (CN)
Zhejiang University, Key Research and Development Program of Zhejiang Province
Good health and well-being
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon